QCG
CRBP icon

Quadrant Capital Group’s Corbus Pharmaceuticals CRBP Stock Holding History

Quadrant Capital Group’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-22
Closed – – 2572
2022
Q1 		$0 Hold
22
– – ﹤0.01% 2523
2021
Q4 		$0 Buy
+22
New +$596 ﹤0.01% 2535

Other funds holding CRBP

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.32B AUM 31.52% 1-Year Est. Return

Quadrant Capital Group's CRBP Position: Q2 2022 in Review

Quadrant Capital Group sold out of Corbus Pharmaceuticals (CRBP) in Q2 2022, closing a stake of 22 shares.

Quadrant Capital Group first reported a position in CRBP in Q4 2021 and held it in 2 quarters. The position peaked at $0 in Q1 2022. 70 funds tracked by Wall St. Rank hold CRBP as of Q2 2022.

  • Quadrant Capital Group reported no remaining Corbus Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Quadrant Capital Group sold 22 Corbus Pharmaceuticals shares in Q2 2022.
  • Quadrant Capital Group first reported a position in Corbus Pharmaceuticals in Q4 2021 and held it in 2 quarters.
  • Quadrant Capital Group's Corbus Pharmaceuticals position peaked at $0 in Q1 2022.
  • 70 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2022.

Based on Quadrant Capital Group's 13F filing for Q2 2022, filed 9 Aug 2022.